Tandem Diabetes strong start to 2024, ups sales guidance

 

• Revenue: Q1 worldwide sales grew 12% year-over-year to $193 million.

• U.S. Sales: First quarter sales of $131 million with approximately 15,000 pump shipments.

• International Sales: Grew over 60% to $62 million with nearly 10,000 pump shipments.

• Gross Margin: Reported at 50%, consistent with the prior year.

• Adjusted EBITDA Margin: Improved nearly 5 percentage points year-over-year to negative 7%.

• Operating Expenses: Increased by 5% on 12% sales growth.

• 2024 Sales Guidance: Increased to approximately $868 million, or 12% growth year-over-year.

• Profitability Guidance: Maintaining full year guidance of 51% for gross margin and breakeven for adjusted EBITDA.

• Q2 Sales Forecast: Worldwide sales anticipated to be $205 million.

• Q2 Gross Margin: Expected to be approximately 50%.

• Q2 Adjusted EBITDA: Expected to improve to negative 5%.

https://finance.yahoo.com/news/tandem-diabetes-care-inc-tndm-080354036.html